What is the clinical evidence from this study?

Study design: Other. Population: Dilated Cardiomyopathy (n=33). Intervention: Enalapril and Valsartan vs. Placebo or Enalapril alone. Primary outcome: 500-day survival rate (p=<0.05).

January 1, 2002Japanese Heart JournalOpen Access

Long-Term Combined Therapy with an Angiotensin Type I Receptor Blocker and an Angiotensin Converting Enzyme Inhibitor Prolongs Survival in Dilated Cardiomyopathy.

Q: What are the key findings of this study?

Combined therapy with enalapril and valsartan significantly increased the 500-day survival rate to 63.6% compared to 16.7% with enalapril alone and 0% with placebo in cardiomyopathic hamsters.

View Full Paper

Ask AI

Bookmark

Key result

Combined therapy with enalapril and valsartan significantly increased the 500-day survival rate to 63.6% compared to 16.7% with enalapril alone and 0% with placebo in cardiomyopathic hamsters.

Why the study?

Does combined therapy with enalapril and valsartan improve survival in cardiomyopathic hamsters compared to enalapril alone or placebo?

Population

Male cardiomyopathic hamsters (BIO TO2) starting at 6 weeks of age

Comparison

Enalapril + valsartan administered orally vs Placebo or enalapril monotherapy (30 mg/kg/day)

Design

Preclinical, randomly assigned

Follow-up

up to 500 days

Authors

TSToshihiro ShimizuInstitute for Infocomm Research HOHiroshi OkamotoThe University of Tokyo SCSatoru ChibaSuzuki (Japan)

Discussion

Member takes

Implication

Should not change human cardiomyopathy practice; hypothesis-generating for combined ACEI/ARB therapy in dilated cardiomyopathy models.

Structured PICO

Does combined therapy with enalapril and valsartan improve survival in cardiomyopathic hamsters compared to enalapril alone or placebo?

Population

33 male cardiomyopathic hamsters (BIO TO2) starting at 6 weeks of age, followed for up to 500 days to assess survival.

Intervention

Enalapril (30 mg/kg/day) + valsartan (500 mg/kg/day) administered orally

Comparator

Placebo or enalapril monotherapy (30 mg/kg/day)

Outcome

Survival (mortality)hard clinical

Main Result

Absolute Event Rate: 63.6% vs 16.7%

p-value: p=<0.05

Combined therapy with an ACE inhibitor and an ARB significantly prolonged survival and improved cardiac function in a hamster model of dilated cardiomyopathy compared to ACE inhibitor monotherapy.

Limitations

The study was conducted in an animal model, which may not directly translate to human clinical outcomes.
The molecular mechanisms responsible for the beneficial effects of the combination therapy were not fully clarified.
The present study has not clarified the molecular mechanisms responsible for the beneficial effects of the combination therapy.

Cite This Study

Shimizu et al. (2002) studied Dilated Cardiomyopathy (n=33). Enalapril and Valsartan vs. Placebo or Enalapril alone was evaluated on 500-day survival rate (p=<0.05). Combined therapy with enalapril and valsartan significantly increased the 500-day survival rate to 63.6% compared to 16.7% with enalapril alone and 0% with placebo in cardiomyopathic hamsters.

synapsesocial.com/papers/6a969e848a4936f1ceb2f5fd https://doi.org/10.1536/jhj.43.531

View Full Paper

Ask AI

Bookmark

Long-Term Combined Therapy with an Angiotensin Type I Receptor Blocker and an Angiotensin Converting Enzyme Inhibitor Prolongs Survival in Dilated Cardiomyopathy.

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Long-Term Combined Therapy with an Angiotensin Type I Receptor Blocker and an Angiotensin Converting Enzyme Inhibitor Prolongs Survival in Dilated Cardiomyopathy.

Discussion

Member takes

Implication

Structured PICO

Main Result

Limitations

Cite This Study

Also Consider

Also Consider